- Solid Tumors
- Pipeline Molecules
- Alliance Partners
Our mission is to provide healthcare professionals with unbiased clinical research information, easily.
Currently, you can access the following clinical trials being conducted worldwide:
Clinicaltrials.gov identifier NCT03931772
Recruitment Status Recruiting
First Posted April 30, 2019
Last update posted April 30, 2019
After developing professional quality materials (audio) for an inexpensive automated self-hypnosis intervention program for treating smoking cessation, researchers aim to gain qualitative reviews of this program, and test its initial feasibility and effects on smoking cessation.
The investigators are interested in recruiting individuals who report that they smoke cigarettes daily, are motivated to make a serious attempt at quitting, and are willing to try to use the hypnosis intervention and provide feedback regarding their experience with the intervention. The intervention would be pre-recorded and programmed to be an interactive hypnotic tool. It will be delivered through Amazon's Alexa device. The participants will be provided with the Alexa Dot device if they already do not possess one. Alexa Dot is a device sold by Amazon and widely used by consumers. What will be specific to this pilot is the interactive nature of the program that has been developed using the "skills beta testing tool" by Amazon. Potential participants will be recruited through websites and social media such as Facebook, flyers and by study Investigator, Dr. David Spiegel (or a member of his staff) who will propose the possibility of participation in the pilot study to patients seen at the clinics who may be eligible; he will also invite his psychiatrist colleagues to do the same for their patients. If the patients indicate that they are interested, they will be contacted by a research coordinator who is a member of Dr. Spiegel's staff. The coordinator will provide them with information about the pilot study, answer their questions, and determine whether the patient is eligible for the study. Eligible participants will be 18 years or older, able to read and understand English, and have a desire to quit smoking. Once found eligible, participants will pay one visit to the lab for about 1 hour, where they will be guided through the online auditory intervention by Dr. Spiegel (or a member of his staff), undergo hypnotizability testing, and complete brief questionnaires. This will take approximately one hour and will take place at The Center on Stress and Health. After the lab visit participants will continue using the intervention at home as needed. Furthermore, participants will be taking an at-home 10-15 minute survey at baseline, and then 1, 3, 6, 12 and 24-month follow-ups
|Other: Automated Self-Hypnosis Intervention
Participants will first try this intervention at their Baseline visit following an assessment of trait hypnotizability. After being guided through the program by their experimenter (i.e., set-up procedures in addition to the actual hypnotic exercise) participants will provide initial feedback on the program through a series of questions. The entire appointment will take approximately one hour and will take place at The Center on Stress and Health. Participants will be provided the Amazon Alexa device to take home (necessary for using the program). After the lab visit participants will continue using the intervention at home as needed (recommended every few hours or whenever they feel the urge to smoke). Furthermore, participants will be taking an at-home 15 minute survey at baseline, and then 1, 3, 6, 12 and 24 month follow-ups.
Behavioral: Automated Self-Hypnosis
Hypnosis is a very safe and validated mind-body technique for symptom management of various clinical problems. The intervention is designed by the protocol's principal investigator, Dr. David Spiegel.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, , Learn About Clinical Studies.-->
- 18 years or older
- Able to read and understand English
- Desire to quit smoking (specifically, report a motivation of ≥ 5 out of 10 to quit
smoking on a 10-point Likert-type scale)
- Having access to wireless internet connection or mobile data
- Reporting being a daily smoker for at least one year, smoking an average ≥ 5
cigarettes per day
- Meeting criteria for drug abuse of depressants, dissociative anesthetics,
hallucinogens, opioids, cocaine, or amphetamine within the last 3 months.
- Severe psychiatric or structural brain disease (i.e. psychosis, stroke with functional
impairment, dementia) or [current/recent risk to self. Indicated by denial of question
pertaining to inpatient hospitalization
- Hearing impairment that would impede ability to listen the auditory intervention
- Major illnesses impacting the study results
- Currently taking Wellbutrin, Chantix, or other pharmacological smoking cessation aids
that could confound results of the study
Contact: Johnna L Medina, PhD 650-497-4489 email@example.com
Contact: Bita Nouriani, MS Bita Nouriani firstname.lastname@example.org
United States, California
Stanford Medicine - Psychiatry and Behavioral Sciences
United States, California
Dept. of Psychiatry, Stanford University
Principal Investigator: David Spiegel Stanford University